Stay updated on PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Sign up to get notified when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.

Latest updates to the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page
- Check6 days agoChange DetectedThe study record is displayed with details about the PEGPH20 and pembrolizumab trial for metastatic pancreatic cancer, including its design, eligibility requirements, outcome measures, and study locations.SummaryDifference69%

- Check13 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA notice about NIH terminology changes appears above the ClinicalTrials.gov page, and the site revision changes from v3.7.1 to v3.7.2. The requested study record remains unavailable behind a 403 error.SummaryDifference1%

- Check41 days agoChange DetectedThe footer site revision changes from v3.7.0 to v3.7.1; the page remains a 403 error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the usual study record content with an inaccessible error screen. The change includes an added 403 header and HTML, and deletions remove the standard study data and navigation.SummaryDifference21%

- Check62 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, indicating a new release of the ClinicalTrials.gov page content. This update is likely administrative and does not change the study information presented to users.SummaryDifference0.0%

Stay in the know with updates to PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEGPH20 & Pembro in High Metastatic PDAC Clinical Trial page.